These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31652369)

  • 1. Italian consensus on treatment of spasticity in multiple sclerosis.
    Comi G; Solari A; Leocani L; Centonze D; Otero-Romero S;
    Eur J Neurol; 2020 Mar; 27(3):445-453. PubMed ID: 31652369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
    Gold R; Oreja-Guevara C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):55-9. PubMed ID: 24289845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
    Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
    Fu X; Wang Y; Wang C; Wu H; Li J; Li M; Ma Q; Yang W
    Clin Rehabil; 2018 Jun; 32(6):713-721. PubMed ID: 29582713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non pharmacological interventions for spasticity in multiple sclerosis.
    Amatya B; Khan F; La Mantia L; Demetrios M; Wade DT
    Cochrane Database Syst Rev; 2013 Feb; (2):CD009974. PubMed ID: 23450612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
    Yelnik AP
    Ann Readapt Med Phys; 2004 Oct; 47(8):575-89. PubMed ID: 15465163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological treatment of spasticity in multiple sclerosis].
    Heinzlef O; Monteil-Roch I
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
    Stien R; Nordal HJ; Oftedal SI; Slettebø M
    Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments for spasticity and pain in multiple sclerosis: a systematic review.
    Beard S; Hunn A; Wight J
    Health Technol Assess; 2003; 7(40):iii, ix-x, 1-111. PubMed ID: 14636486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of spasticity in children with cerebral palsy.
    Chung CY; Chen CL; Wong AM
    J Formos Med Assoc; 2011 Apr; 110(4):215-22. PubMed ID: 21540003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations.
    Borg-Stein J; Pine ZM; Miller JR; Brin MF
    Am J Phys Med Rehabil; 1993 Dec; 72(6):364-8. PubMed ID: 8260129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
    Schapiro RT
    Curr Neurol Neurosci Rep; 2001 May; 1(3):299-302. PubMed ID: 11898533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
    PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.